However, these treatments fail to achieve rigorous metabolic control in more than 50% of T2DM cases, necessitating the search for novel antidiabetic agents that mimic or enhance the properties of insulin, as well as protect against diabetic complications. The gene discussed is INS; the disease is type 2 diabetes mellitus.